Abstract:

The currently accepted treatment for neovascular age\|related macular degeneration (nAMD) is anti\|vascular endothelial growth factor (VEGF). Based on the clinical data of ranibizumab, the clinical application of anti\|VEGF is continuously optimized. At present, the treatment of ranibizumab mainly includes:  monthly treatment plan, bi\|month treatment plan, quarterly treatment plan, on\|demand treatment (Pro Re Nata, PRN) program, treatment and extension program, observation and plan plan. The initial monthly treatment plan can give patients a significant increase in vision; however, monthly treatment can place a huge financial burden on patients. The PRN program, every two months of treatment, and quarterly treatments can reduce the number of vitreous injections in patients, thereby reducing the financial burden on patients, while treatment and extension programs not only reduce the number of injections, but also reduce the number of follow\|ups. It also saves time and burden while reducing economic costs. (Int Rev Ophthalmol, 2019, 43:  111-117)